The first-line effect of bortezomib-based therapy on clinical outcomes for Taiwanese patients with multiple myeloma

被引：0
|
作者：
Ho, C-L. [1 ]
Chen, J-H. [1 ]
机构：
[1] Triserv Gen Hosp, Natl Def Med Ctr, Dept Med, Taipei, Taiwan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1087P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma
    Bumma, Naresh
    Dhakal, Binod
    Fraser, Raphael
    Estrada-Merly, Noel
    Anderson, Kenneth
    Freytes, Cesar O.
    Hildebrandt, Gerhard C.
    Holmberg, Leona
    Krem, Maxwell M.
    Lee, Cindy
    Lekakis, Lazaros
    Lazarus, Hillard M.
    Mian, Hira
    Murthy, Hemant S.
    Nathan, Sunita
    Nishihori, Taiga
    Parrondo, Ricardo
    Patel, Sagar S.
    Solh, Melhem
    Strouse, Christopher
    Vesole, David H.
    Kumar, Shaji
    Qazilbash, Muzaffar H.
    Shah, Nina
    D'Souza, Anita
    Sidana, Surbhi
    CANCER, 2023, 129 (14) : 2179 - 2191
  • [22] The role of lenalidomide-dexamethasone therapy in elderly patients with multiple myeloma in clinical practice: comparison with bortezomib-based therapy
    Kwon, Jihyun
    Lee, Yong-Pyo
    Park, Hee Sue
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S101 - S101
  • [23] BORTEZOMIB IN THE FIRST-LINE TREATMENT OF MULTIPLE MYELOMA: THE EXPERIENCE OF A CENTER
    Mendes, M. J.
    Ferreira, G.
    Saturnino, H.
    Duarte, M.
    Almeida, J. C.
    Arajo, L. F.
    Ribeiro, M. L.
    HAEMATOLOGICA, 2015, 100 : 735 - 735
  • [24] The effect of bortezomib monotherapy and bortezomib-based regimens on bone metabolism in patients with relapsed/refractory multiple myeloma
    Terpos, E.
    Heath, D. J.
    Zervas, K.
    Anagnostopoulos, A.
    Katodritou, E.
    Christoulas, D.
    Pouli, A.
    Chantry, A.
    Anargyrou, K.
    Kastritis, E.
    Verrou, E.
    Tsionos, K.
    Croucher, P.
    Dimopoulus, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 133 - 134
  • [25] Clinical efficacy of thalidomide containing regimens as a first-line therapy in patients with multiple myeloma
    Kim, Y. K.
    Lee, J. J.
    Lee, S. R.
    Shim, H. J.
    Ahn, J. S.
    Yang, D. H.
    Cho, S. H.
    Chung, I. J.
    Kim, D. H.
    Sohn, S. K.
    Shin, H. J.
    Kim, H. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 177 - 177
  • [26] Bortezomib thalidomide dexamethasone as first-line treatment in Newly Multiple Myeloma Patients in Peru
    Vasquez, Jule
    Castillo, Claudia
    Lopez, Naty
    Quintana, Shirley
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S248 - S248
  • [27] Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study
    Oriol, Albert
    Giraldo, Pilar
    Kotsianidis, Ioannis
    Couturier, Catherine
    Olie, Robert
    Angermund, Ralf
    Corso, Alessandro
    HEMATOLOGY, 2015, 20 (07) : 405 - 409
  • [28] Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
    Cavo, Michele
    Bringhen, Sara
    Testoni, Nicoletta
    Omede, Paola
    Marzocchi, Giulia
    Ruggeri, Marina
    Durante, Sandra
    Di Raimondo, Francesco
    Rossi, Davide
    Gorgone, Ausilia
    Patriarca, Francesca
    Petrucci, Maria Teresa
    Buttignol, Silvia
    Levi, Anna
    Offidani, Massimo
    Nozzoli, Chiara
    Ria, Roberto
    Olivero, Barbara
    Galli, Monica
    Montefusco, Vittorio
    Callea, Vincenzo
    Falcone, Antonietta
    De Vivo, Antonio
    Boccadoro, Mafio
    Terragna, Carolina
    Palumbo, Antonio
    BLOOD, 2009, 114 (22) : 741 - 741
  • [29] NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma
    Doss, Sally
    Hay, Nicola
    Sutcliffe, Frances
    LANCET ONCOLOGY, 2011, 12 (09): : 837 - 838
  • [30] Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma
    Zou, Yandun
    Sheng, Zhixin
    Niu, Shaona
    Wang, Huijuan
    Yu, Jinming
    Xu, Jingbo
    LEUKEMIA & LYMPHOMA, 2013, 54 (10) : 2219 - 2225
12345